NCT03340610View on ClinicalTrials.gov

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 12, 2018

Conditions
Diabetic Macular Edema
Interventions
DRUG

Alflibercept

Intravitreal Injection

Trial Locations (1)

30809

Southeast Retina Center, Augusta

All Listed Sponsors
lead

Southeast Retina Center, Georgia

OTHER

NCT03340610 - IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab | Biotech Hunter | Biotech Hunter